NL8620004A - Verbeteringen met betrekking tot virale isolaten en toepassing daarvan. - Google Patents
Verbeteringen met betrekking tot virale isolaten en toepassing daarvan. Download PDFInfo
- Publication number
- NL8620004A NL8620004A NL8620004A NL8620004A NL8620004A NL 8620004 A NL8620004 A NL 8620004A NL 8620004 A NL8620004 A NL 8620004A NL 8620004 A NL8620004 A NL 8620004A NL 8620004 A NL8620004 A NL 8620004A
- Authority
- NL
- Netherlands
- Prior art keywords
- retrovirus
- human
- globulin
- cbl
- htlv
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title description 10
- 239000000427 antigen Substances 0.000 claims description 80
- 102000036639 antigens Human genes 0.000 claims description 80
- 108091007433 antigens Proteins 0.000 claims description 80
- 238000012360 testing method Methods 0.000 claims description 58
- 241001430294 unidentified retrovirus Species 0.000 claims description 53
- 210000002966 serum Anatomy 0.000 claims description 43
- 239000007790 solid phase Substances 0.000 claims description 40
- 208000030507 AIDS Diseases 0.000 claims description 31
- 108010044091 Globulins Proteins 0.000 claims description 29
- 102000006395 Globulins Human genes 0.000 claims description 29
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 11
- 108090000790 Enzymes Proteins 0.000 claims description 11
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims description 11
- 239000007791 liquid phase Substances 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 4
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 3
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 38
- 238000003556 assay Methods 0.000 description 31
- 241000700605 Viruses Species 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 18
- 238000002965 ELISA Methods 0.000 description 17
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 241000725303 Human immunodeficiency virus Species 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 230000009257 reactivity Effects 0.000 description 12
- 239000004793 Polystyrene Substances 0.000 description 11
- 229920002223 polystyrene Polymers 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 238000012875 competitive assay Methods 0.000 description 9
- 230000002860 competitive effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 238000003127 radioimmunoassay Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 229940098773 bovine serum albumin Drugs 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 229920001213 Polysorbate 20 Polymers 0.000 description 7
- 238000010166 immunofluorescence Methods 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 229960000380 propiolactone Drugs 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000009292 Hemophilia A Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010053574 Immunoblastic lymphoma Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229950000038 interferon alfa Drugs 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 206010001513 AIDS related complex Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101150111781 PGL1 gene Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 208000005074 Retroviridae Infections Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/804—Radioisotope, e.g. radioimmunoassay
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/809—Multifield plates or multicontainer arrays
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/81—Tube, bottle, or dipstick
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/823—Immunogenic carrier or carrier per se
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8500918 | 1985-01-15 | ||
| GB858500918A GB8500918D0 (en) | 1985-01-15 | 1985-01-15 | Viral isolates |
| US75660485A | 1985-07-19 | 1985-07-19 | |
| US75660485 | 1985-07-19 | ||
| PCT/GB1986/000023 WO1986004423A1 (en) | 1985-01-15 | 1986-01-13 | Improvements relating to viral isolates and their use |
| GB8600023 | 1986-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8620004A true NL8620004A (nl) | 1986-12-01 |
Family
ID=26288664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8620004A NL8620004A (nl) | 1985-01-15 | 1986-01-13 | Verbeteringen met betrekking tot virale isolaten en toepassing daarvan. |
Country Status (15)
| Country | Link |
|---|---|
| AT (1) | ATA900186A (xx) |
| AU (1) | AU591647B2 (xx) |
| BE (1) | BE904030A (xx) |
| BR (1) | BR8604533A (xx) |
| CH (1) | CH675636A5 (xx) |
| DE (2) | DE3690028T (xx) |
| DK (1) | DK437386A (xx) |
| FI (1) | FI863704A0 (xx) |
| FR (1) | FR2576107B1 (xx) |
| GB (1) | GB2179449B (xx) |
| HU (1) | HU204929B (xx) |
| IT (1) | IT1191841B (xx) |
| NL (1) | NL8620004A (xx) |
| SE (1) | SE8603803L (xx) |
| WO (1) | WO1986004423A1 (xx) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8500918D0 (en) * | 1985-01-15 | 1985-02-20 | Cancer Res Inst | Viral isolates |
| EP0193284B1 (en) * | 1985-02-05 | 1990-07-18 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | A method for detecting htlv-iii neutralizing antibodies in sera |
| AU579715B2 (en) * | 1985-02-26 | 1988-12-08 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Detection of human t-cell leukemia virus type iii |
| US4748110A (en) * | 1985-09-25 | 1988-05-31 | Abbott Laboratories | Immunoassay for HTLV-III antigens |
| US4839288A (en) * | 1986-01-22 | 1989-06-13 | Institut Pasteur | Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes |
| US6514691B1 (en) | 1986-01-22 | 2003-02-04 | Institut Pasteur | Peptides of human immunodeficiency virus type 2 (HIV-2), antibodies against peptides of HIV-2, and methods and kits for detecting HIV-2 |
| US5364933A (en) * | 1986-03-03 | 1994-11-15 | Institut Pasteur | Methods of immunopurification of antigens of human immunodeficiency virus type 2 (HIV-2) |
| CA1278259C (en) * | 1986-02-26 | 1990-12-27 | William C. Saxinger | Competitive elisa for the detection of antibodies |
| US4904581A (en) * | 1986-05-06 | 1990-02-27 | Epitope, Inc. | Method of detecting AIDS virus infection |
| SE8701765L (sv) * | 1987-04-28 | 1988-10-29 | Statens Bakteriologiska Lab | Analysmetod och medel foer denna |
| DE3877294T2 (de) * | 1987-09-04 | 1993-05-06 | Int Murex Tech Corp | Festphasenimmunoassay fuer einen antikoerper und hierbei verwendete biologische produkte. |
| US5115098A (en) * | 1990-02-28 | 1992-05-19 | President And Fellows Of Harvard College | End-blocked peptides inhibiting binding capacity of gp120 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2016687B (en) * | 1978-03-20 | 1982-09-08 | Abbott Lab | Sugar coated reagents for solid phase immunoassay |
| EP0136798A3 (en) * | 1983-08-25 | 1986-02-19 | Biotech Research Laboratories Inc. | Titre plate and assay kit for detection of antibodies in human serum and their production and use |
| IE58321B1 (en) * | 1984-04-23 | 1993-09-08 | Us Health | Isolation of proteins of HTLV-III, serological detection of antibodies to HTLV-III in sera of patients with aids and pre-aids conditions, and detection of HTLV-III infection bi/immuno-assays using HTLV-III infection by immuno-assays using HTLV-III and its proteins |
| US4652599A (en) * | 1984-04-23 | 1987-03-24 | The United States Of America As Represented By The Department Of Health And Human Services | Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS using permissive cells |
| US4520113A (en) * | 1984-04-23 | 1985-05-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions |
| AU580425B2 (en) * | 1985-05-24 | 1989-01-12 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Competitive elisa for the detection of antibodies |
-
1986
- 1986-01-13 DE DE19863690028 patent/DE3690028T/de active Pending
- 1986-01-13 BE BE0/216129A patent/BE904030A/fr not_active IP Right Cessation
- 1986-01-13 GB GB08620371A patent/GB2179449B/en not_active Expired
- 1986-01-13 DE DE3690028A patent/DE3690028C2/de not_active Expired - Lifetime
- 1986-01-13 FR FR868600376A patent/FR2576107B1/fr not_active Expired - Lifetime
- 1986-01-13 NL NL8620004A patent/NL8620004A/nl unknown
- 1986-01-13 CH CH3710/86A patent/CH675636A5/de not_active IP Right Cessation
- 1986-01-13 IT IT19072/86A patent/IT1191841B/it active
- 1986-01-13 AU AU52385/86A patent/AU591647B2/en not_active Ceased
- 1986-01-13 BR BR8604533A patent/BR8604533A/pt unknown
- 1986-01-13 WO PCT/GB1986/000023 patent/WO1986004423A1/en active Application Filing
- 1986-01-13 HU HU86767A patent/HU204929B/hu unknown
- 1986-01-13 AT AT0900186A patent/ATA900186A/de not_active Application Discontinuation
- 1986-09-11 SE SE8603803A patent/SE8603803L/xx not_active Application Discontinuation
- 1986-09-12 FI FI863704A patent/FI863704A0/fi not_active Application Discontinuation
- 1986-09-12 DK DK437386A patent/DK437386A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SE8603803D0 (sv) | 1986-09-11 |
| GB2179449A (en) | 1987-03-04 |
| HUT41129A (en) | 1987-03-30 |
| FR2576107A1 (fr) | 1986-07-18 |
| BE904030A (fr) | 1986-07-14 |
| AU5238586A (en) | 1986-08-13 |
| DK437386D0 (da) | 1986-09-12 |
| BR8604533A (pt) | 1987-07-14 |
| WO1986004423A1 (en) | 1986-07-31 |
| AU591647B2 (en) | 1989-12-14 |
| DE3690028T (xx) | 1987-03-12 |
| HU204929B (en) | 1992-02-28 |
| SE8603803L (sv) | 1986-09-11 |
| GB8620371D0 (en) | 1986-10-01 |
| FI863704A (fi) | 1986-09-12 |
| GB2179449B (en) | 1988-12-21 |
| FR2576107B1 (fr) | 1990-08-31 |
| CH675636A5 (xx) | 1990-10-15 |
| DE3690028C2 (de) | 1995-05-24 |
| DK437386A (da) | 1986-09-12 |
| IT1191841B (it) | 1988-03-23 |
| ATA900186A (de) | 1993-12-15 |
| IT8619072A0 (it) | 1986-01-13 |
| FI863704A0 (fi) | 1986-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Paul et al. | Correlation of serum HIV antigen and antibody with clinical status in HIV‐I infected patients | |
| JP2626721B2 (ja) | Ｈｔｌｖ―３の蛋白質の分離、エイズおよび前エイズ条件を持つ患者の血清中ｈｔｌｖ―３に対する抗体の血清学的検出、およびｈｔｌｖ―３およびその蛋白質を使用した免疫分析によるｈｔｌｖ―３感染の検出 | |
| US4870003A (en) | Simultaneous enzyme immunoassay for detecting antigen and/or antibody in humans | |
| US5039604A (en) | Test device and method of preparing same, assay kit and method for the simultaneous detection of two HTLV or HIV antibodies | |
| IE58321B1 (en) | Isolation of proteins of HTLV-III, serological detection of antibodies to HTLV-III in sera of patients with aids and pre-aids conditions, and detection of HTLV-III infection bi/immuno-assays using HTLV-III infection by immuno-assays using HTLV-III and its proteins | |
| JPH076983B2 (ja) | 抗体の迅速検出のための組成物、診断キット及び方法 | |
| NL8620004A (nl) | Verbeteringen met betrekking tot virale isolaten en toepassing daarvan. | |
| CA1305411C (en) | Method for the determination of anti-hiv, means therefore and theiruse in this method | |
| US4912030A (en) | Viral isolates and their use in diagnosis | |
| EP0386713B1 (en) | Immunoassay for antibodies to HIV | |
| US4877725A (en) | Immunoassays for antibodies which bind to the acquired immunodeficiency virus | |
| Goswami et al. | Intrathecal IgG synthesis and specificity of oligoclonal IgG in patients infected with HIV‐1 do not correlate with CNS disease | |
| JP3889045B2 (ja) | Ｈｉｖを検出するためのペプチド | |
| Neurath et al. | Radioimmunoassay and enzyme-linked immunoassay of antibodies to the core protein (P24) of human T-lymphotropic virus (HTLV III) | |
| Beristain et al. | Evaluation of a dipstick method for the detection of human immunodeficiency virus infection | |
| RU2283497C1 (ru) | ИММУНОФЕРМЕНТНАЯ ТЕСТ-СИСТЕМА ДЛЯ ИДЕНТИФИКАЦИИ СПЕКТРА АНТИТЕЛ К ВИЧ 1 И 2 ВЫЯВЛЕНИЯ АНТИГЕНА ВИЧ 1 (p24) "ДС-ИФА-АНТИ-ВИЧ 1 И 2, ВИЧ 1 ГРУППЫ О-СПЕКТР+АГ p24 ВИЧ 1" | |
| Singh et al. | Enzyme-linked immunosorbent assay in the diagnosis of Kilham rat virus infection in rats | |
| EP0233061B1 (en) | Reagent for detecting antibody to viral antigen | |
| US5811282A (en) | Cell lines useful for detection of human immunodeficiency virus | |
| Krust et al. | A sensitive dot immunobinding assay for the detection of antibodies specific for HIV | |
| Levinson et al. | Strengths and weaknesses in methods for identifying the causative agent (s) of acquired immunodeficiency syndrome (AIDS) | |
| Kontio | Sensitive one-step enzyme immunoassay for HIV-1 p24 antigen in human blood specimens and cell culture supernatants | |
| EP0954614A1 (en) | Method and composition for the diagnosis of equine infectious anemia virus disease by using the recombinant capsid protein virus (p26) | |
| US4956292A (en) | Viral strain isolated from cerebrospinal fluid of an HIV seropositive man having acute and regressive encephalopathy and use of the strain in an immunoassay | |
| Montagna et al. | Evaluation of a solid-phase immunoassay for the simultaneous detection of antibodies to human immunodeficiency virus type 1 and human T-cell lymphotropic virus type I |